News Conference News AHA 2022 Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5 Yael L. Maxwell November 11, 2022
News Conference News AHA 2022 Chinese Medicine Tongxinluo Yields ‘Surprising’ Benefits Post-STEMI: CTS-AMI Shelley Wood November 10, 2022
News Conference News AHA 2022 RESPECT-EPA: Missed Primary Endpoint but Hints of Benefit With Icosapent Ethyl Todd Neale November 10, 2022
News Conference News AHA 2022 Another OPTION? Indobufen Noninferior to Aspirin Following Successful PCI Yael L. Maxwell November 10, 2022
Presentation AHA 2022 Reduction of Lipoprotein(a) With Small Interfering RNA: Results of the OCEAN(a)-DOSE (TIMI 67) Trial Presenter: Michelle L. O’Donoghue November 07, 2022
Presentation AHA 2022 Comparison of a Precision Care Strategy With Usual Testing To Guide Management Of Stable Patients With Suspected Coronary Artery Disease Presenter: Pamela S. Douglas November 07, 2022
Presentation AHA 2022 Bivalirudin Plus a High-dose Infusion Versus Heparin Monotherapy in Patients with STEMI Undergoing Primary PCI: The BRIGHT-4 Trial Presenter: Gregg W. Stone November 07, 2022
News Conference News AHA 2022 ISCHEMIA-EXTEND: So Far, Deaths Match for Invasive and Conservative Arms in Stable CAD Shelley Wood November 06, 2022
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Conference News AHA 2022 ‘Dramatic’ Reductions in Lp(a) With Olpasiran: OCEAN(a)-DOSE Michael O'Riordan November 06, 2022
News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Conference News AHA 2022 High-Sensitivity Troponin Testing on the Rise in the US but Still Limited Michael O'Riordan November 04, 2022